Gut Healing Protocol

Overview

The gastrointestinal tract is lined by a single layer of epithelial cells that forms a selective barrier between the intestinal lumen and the bloodstream. When this barrier is compromised — a condition commonly referred to as increased intestinal permeability — it can contribute to systemic inflammation, immune dysregulation, and a range of downstream health concerns.

Peptide-based gut healing protocols focus on restoring the integrity of this epithelial barrier, reducing localized inflammation, and supporting mucosal repair. The two primary peptides used in this context are BPC-157 and KPV, each targeting different aspects of gut pathology.

A distinguishing feature of this protocol is the emphasis on oral administration. While most peptides are administered by injection due to gastrointestinal degradation, BPC-157 is one of the few peptides that retains biological activity when taken orally — in fact, it was originally derived from gastric juice and appears to exert significant local effects throughout the GI tract when delivered orally.

Compounds Involved

BPC-157 for Gut Applications

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice that has been studied extensively for its protective effects on the gastrointestinal mucosa. Research has demonstrated effects including accelerated healing of gastric ulcers, protection against NSAID-induced gut damage, repair of intestinal anastomoses, and modulation of the gut-brain axis through nitric oxide and dopamine pathways.

For gut-specific applications, oral BPC-157 delivers the peptide directly to the site of action — the gastrointestinal lining. This local delivery may provide advantages over systemic (injectable) administration for GI-specific concerns.

KPV

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has been studied for its potent anti-inflammatory properties, particularly its ability to inhibit NF-kB — a master transcription factor in inflammatory signaling. In the context of gut health, KPV has shown activity in reducing intestinal inflammation and protecting mucosal tissue in preclinical inflammatory bowel models.

KPV's small size (just three amino acids) contributes to its stability and makes it a candidate for oral administration, though it is also used subcutaneously.

Protocol Structure

Phase 1: Acute Repair (Weeks 1–4)

The initial phase uses higher frequency dosing to address active gut barrier compromise.

BPC-157 (oral):

• Dose: 250–500 mcg, twice daily
• Timing: Morning on an empty stomach, and evening before bed (at least 2 hours after the last meal)
• Method: Capsule, sublingual solution, or reconstituted solution swallowed directly (see Oral Administration)

KPV (oral or SubQ):

• Dose: 200–500 mcg, once or twice daily
• Timing: Morning on an empty stomach
• Route: Oral capsule preferred for gut-specific applications; SubQ for combined systemic and local effects

Phase 2: Maintenance and Restoration (Weeks 5–12)

The maintenance phase reduces dosing while continuing to support mucosal integrity.

BPC-157 (oral):

• Dose: 250 mcg, once daily
• Timing: Morning on an empty stomach

KPV (oral):

• Dose: 200 mcg, once daily
• Timing: Morning on an empty stomach

Protocol Summary

Oral Administration Details

For a complete guide to oral peptide delivery, see Oral Administration. Key considerations for this protocol:

BPC-157 Oral Methods

1. Capsules: Pre-measured BPC-157 in acid-resistant capsules designed to survive stomach acid. Some formulations use enteric coatings for targeted release in the small intestine.
2. Sublingual: Reconstituted BPC-157 held under the tongue for 60–90 seconds before swallowing. This allows partial absorption through the sublingual mucosa with the remainder continuing through the GI tract.
3. Direct oral solution: Reconstituted BPC-157 (using bacteriostatic water) swallowed directly. Simple and effective, though taste may be slightly unpleasant.

Fasting Considerations

Oral peptides for gut healing are best taken on an empty stomach:

• No food for at least 30 minutes before and 30 minutes after administration
• Water is acceptable
• Morning administration upon waking is the most practical timing

Supporting Interventions

Peptides work within the context of a gut-supportive environment. The following complement this protocol:

• Dietary modifications: Reducing inflammatory foods (processed foods, refined sugars, seed oils, alcohol) during the protocol supports mucosal healing
• L-Glutamine: 5–10 grams daily, an amino acid that serves as the primary fuel source for intestinal epithelial cells
• Zinc carnosine: 75–150 mg daily, studied for its protective effects on gastric mucosa
• Probiotics: Species-specific probiotic supplementation to support microbiome balance
• Bone broth or collagen: Provides glycine, proline, and glutamine — amino acids involved in mucosal repair
• Stress management: Chronic stress impairs gut barrier function through cortisol-mediated pathways. Selank (see Cognitive Enhancement Protocol) has been studied for both anxiolytic and immune-modulating properties

Oral vs. Injectable BPC-157 for Gut Applications

Some protocols use both routes simultaneously — oral BPC-157 for direct GI effects and injectable BPC-157 near an injury site for systemic tissue repair.

Important Considerations

• Root cause matters: Peptides support healing, but identifying and addressing the underlying cause of gut barrier compromise (food sensitivities, chronic stress, medications, dysbiosis) is essential for lasting results.
• NSAID interaction: BPC-157 has been studied for its protective effects against NSAID-induced gastric damage. However, ongoing NSAID use during a gut healing protocol is counterproductive. Discuss alternatives with a healthcare provider.
• Progress is gradual: Gut barrier restoration is a slow process. Meaningful changes typically develop over weeks to months, not days.
• Testing: Pre- and post-protocol intestinal permeability testing (lactulose-mannitol test, zonulin levels) can help assess progress objectively.
• Cycling: For protocols extending beyond 12 weeks, periodic breaks are recommended. See Peptide Cycling.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.